Eptinezumab 100 mg | Placebo | ||
---|---|---|---|
Optimization subgroup | Time point | Mean (SD) [n] | Mean (SD) [n] |
Very poor | Baseline | 69.6 (4.6) [25] | 66.6 (4.6) [25] |
Week 4 | 58.4 (11.8) [25] | 64.5 (7.5) [24] | |
Change from baseline | -11.2 (12.2) [25] | -2.2 (6.9) [24] | |
Poor | Baseline | 65.0 (4.6) [138] | 66.0 (4.6) [117] |
Week 4 | 57.1 (9.5) [130] | 62.0 (7.8) [114] | |
Change from baseline | -7.7 (10.3) [130] | -4.0 (7.2) [114] | |
Moderate | Baseline | 64.7 (4.6) [46] | 63.2 (5.2) [65] |
Week 4 | 57.3 (8.9) [44] | 59.4 (7.6) [63] | |
Change from baseline | -7.1 (9.0) [44] | -3.8 (8.5) [63] | |
Maximal | Baseline | 63.5 (5.2) [29] | 62.5 (4.8) [35] |
Week 4 | 54.7 (10.1) [27] | 58.7 (7.8) [31] | |
Change from baseline | -8.6 (11.0) [27] | -3.6 (8.4) [31] | |
Simplified subgroups | |||
Poorly optimized | Baseline | 65.7 (4.9) [163] | 66.1 (4.6) [142] |
Week 4 | 57.3 (9.9) [155] | 62.4 (7.7) [138] | |
Change from baseline | -8.3 (10.7) [155] | -3.7 (7.2) [138] | |
Optimized | Baseline | 64.3 (4.8) [75] | 62.9 (5.0) [100] |
Week 4 | 56.4 (9.4) [71] | 59.2 (7.6) [94] | |
Change from baseline | -7.7 (9.7) [71] | -3.7 (8.5) [94] |